Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 2, 2009

Pfizer Taps Xencor for Antibody-Optimizing Technology

  • Pfizer will evaluate the application of Xencor’s Xtend™ antibody half-life prolongation technology and XmAb® ADCC enhancing technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.

    Xencor will receive an up-front payment and is eligible to considerations based on the successful commercialization of products that incorporate the Xencor technology.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.